环指蛋白家族在乳腺癌中作用机制的研究进展

doi:10.16352/j.issn.1001-6325.2026.01.0124

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (1): 124-128.doi: 10.16352/j.issn.1001-6325.2026.01.0124

环指蛋白家族在乳腺癌中作用机制的研究进展

李彬凤¹, 吕发友², 易辉君³, 吕侣^1,2*

1.桂林医科大学第一临床医学院,广西桂林 541000;
2.柳州市人民医院乳甲外科,广西柳州 545000;
3.桂林医科大学第一附属医院广西胃癌早诊早治临床医学研究中心,广西桂林 541000

收稿日期:2024-12-26 修回日期:2025-04-29 出版日期:2026-01-05 发布日期:2025-12-29
通讯作者: ^*156272216@qq.com
基金资助:
国家自然科学基金(82260564);柳州市科技计划(2024YB0101A003)

Advances in the mechanism of action of the ring finger proteins family in breast cancer

LI Binfeng¹, LYU Fayou², YI Huijun³, LYU Lyu^1,2*

1. The First School of Clinical Medicine, Guilin Medical University, Guilin 541000;
2. Department of Breast and Thyroid Surgery, Liuzhou People's Hospital, Liuzhou 545000;
3. Guangxi Clinical Medical Research Center for Early Diagnosis and Treatment of Gastric Cancer, the First Affiliated Hospital of Guilin Medical University, Guilin 541000, China

Received:2024-12-26 Revised:2025-04-29 Online:2026-01-05 Published:2025-12-29
Contact: ^*156272216@qq.com

摘要/Abstract

摘要： 环指蛋白(RNFs)家族不仅在蛋白质降解过程中发挥E3泛素连接酶作用,还广泛调控细胞增殖、凋亡、DNA损伤修复、肿瘤免疫逃逸和表观遗传等过程。RNFs通过激活特定信号通路和调节基因表达,促进乳腺癌细胞增殖和存活。其通过促进DNA损伤修复,维持基因组稳定并增强耐药性;在肿瘤免疫逃逸中,泛素化修饰免疫检查点分子,抑制抗肿瘤免疫反应;在表观遗传调控中,调节DNA甲基化和组蛋白修饰,抑制抑癌基因表达,促进癌细胞增殖和耐药。靶向RNFs可抑制肿瘤生长,提高乳腺癌治疗效果。

关键词: 环指蛋白家族, 乳腺癌, 泛素化, 治疗靶点

Abstract: The ring finger proteins(RNFs) family not only function as E3 ubiquitin ligases involved in protein degradation, but also plays crucial roles in regulating various cellular processes such as proliferation, apoptosis, DNA damage repair, tumor immune escape and epigenetic modification. RNFs promote breast cancer cell proliferation and survival by activating specific signaling pathways and modulating gene expression. By facilitating DNA damage repair, they contribute to genomic stability and enhance resistance to therapy. In the context of tumor immune evasion, RNFs mediate the ubiquitination of immune checkpoint molecules, thereby inhibiting anti-tumor immune responses. Furthermore, in epigenetic regulation, RNFs influence DNA methylation and histone modifications to suppress the expression of tumor suppressor genes, thus promoting cancer cell proliferation and drug resistance. Targeting RNFs may inhibit tumor growth and improve therapeutic outcomes in breast cancer.

Key words: ring finger proteins, breast cancer, ubiquitination, therapeutic target

中图分类号:

R737.9

李彬凤, 吕发友, 易辉君, 吕侣. 环指蛋白家族在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2026, 46(1): 124-128.

LI Binfeng, LYU Fayou, YI Huijun, LYU Lyu. Advances in the mechanism of action of the ring finger proteins family in breast cancer[J]. Basic & Clinical Medicine, 2026, 46(1): 124-128.

参考文献

[1]Tang CT, Liu Z de, Wang P, et al. Lipopolysaccharide-regulated RNF31/NRF2 axis in colonic epithelial cells mediates homeostasis of the intestinal barrier in ulcerative colitis[J]. Cellular Signalling, 2024, 124:111480. doi:10.1016/j.cellsig.2024.111480.
[2]Liu Y, Chen P, Qi D, et al. Glaucocalyxin a inhibits the malignancies of gastric cancer cells by downregulating MDM2 and RNF6 via miR-3658 and the SMG1-UPF mRNA decay pathway[J]. Front Oncol, 2022, 12:871169. doi:10.3389/fonc.2022.871169.
[3]Liu Y, Ouyang L, Mao C, et al. Inhibition of RNF182 mediated by bap promotes non-small cell lung cancer progression[J]. Front Oncol, 2023, 12:1009508. doi:10.3389/fonc.2022.1009508.
[4]Zou L, Sun L, Hua R, et al. Degradation of ubiquitin-editing enzyme A20 following autophagy activation promotes RNF168 nuclear translocation and NF-κB activation in lupus nephritis[J]. J Innate Immun, 2023, 15:428-441. doi:10.1159/000527624.
[5]Xue C, Meng H, Niu W, et al. TRIM28 promotes tumor growth and metastasis in breast cancer by targeting the BRD7 protein for ubiquitination and degradation[J]. Cell Oncol, 2024, 47:1973-1993. doi:10.1007/s13402-024-00981-3.
[6]Zhu J, Zhao C, Zhuang T, et al. RING finger protein 31 promotes p53 degradation in breast cancer cells[J]. Oncogene, 2016, 35:1955-1964. doi:10.1038/onc.2015.260.
[7]Chen X, Su W, Chen J, et al. RNF123 inhibits cell viability, cell cycle and colony formation of breast cancer by inhibiting glycolysis via ubiquitination of PFKP[J]. Naunyn-Schmiedeberg's Arch Pharmacol, 2024. doi:10.1007/s00210-024-03723-2.
[8]Li Z, Li Y, Han D, et al. CircRNA-SFMBT2 orchestrates ERα activation to drive tamoxifen resistance in breast cancer cells[J]. Cell Death Dis, 2023, 14:482. doi:10.1038/s41419-023-06006-5.
[9]Yuan L, Li X, Yang H, et al. The ubiquitin ligase RNF2 stabilizes ERα and modulates breast cancer progression[J]. Hum Cell, 2022, 36:353-365. doi:10.1007/s13577-022-00810-5.
[10]Han D, Wang L, Long L, et al. The E3 ligase TRIM4 facilitates SET ubiquitin-mediated degradation to enhance ER-α action in breast cancer[J]. Adv Sci, 2022, 9:2201701. doi:10.1002/advs.202201701.
[11]Zheng M, Liu W, Zhang R, et al. E3 ubiquitin ligase BCA2 promotes breast cancer stemness by up-regulation of SOX9 by LPS[J]. Int J Biol Sci. 2024, 20:2686-2697. doi:10.7150/ijbs.92338.
[12]Hu A, Zhang L, Cao L, et al. RNF135 promotes the stemness of breast cancer cells by ubiquitinating and degrading DDX58[J]. Transl Oncol, 2025, 54:102321. doi:10.1016/j.tranon.2025.102321.
[13]Huang Y, Zou Y, Jie Z. RNF6 promotes the migration and invasion of breast cancer by promoting the ubiquitination and degradation of MST1[J]. Exp Ther Med, 2021, 23:118. doi:10.3892/etm.2021.11041.
[14]Zhou R, Ding Y, Xue M, et al. RNF181 modulates hippo signaling and triple negative breast cancer progression[J]. Cancer Cell Int, 2020, 20:291. doi:10.1186/s12935-020-01397-3.
[15]Hu Y, Jiang N, Wang X, et al. Systematic pan-cancer analysis of RNF186 with potential implications in progression and prognosis in human cancer[J]. Life Sci, 2024, 338:122389. doi:10.1016/j.lfs.2023.122389.
[16]Liu W, Zheng M, Zhang R, et al. RNF126-mediated MRE11 ubiquitination activates the DNA damage response and confers resistance of triple-negative breast cancer to radiotherapy[J]. Adv Sci, 2023, 10:2203884. doi:10.1002/advs.202203884.
[17]Pan Y, Yang Y, Huang R, et al. Ring finger protein 126 promotes breast cancer metastasis and serves as a potential target to improve the therapeutic sensitivity of ATR inhibitors[J]. Breast Cancer Res, 2022, 24:92. doi:10.1186/s13058-022-01586-0.
[18]Zhu Q, Huang J, Huang H, et al. RNF19A-mediated ubiquitination of BARD1 prevents BRCA1/BARD1-dependent homologous recombination[J]. Nat Commun, 2021, 12:6653. doi:10.1038/s41467-021-27048-3.
[19]Krishnan R, Lapierre M, Gautreau B, et al. RNF8 ubiquitylation of XRN2 facilitates R-loop resolution and restrains genomic instability in BRCA1 mutant cells[J]. Nucleic Acids Res, 2023, 51:10484-10505. doi:10.1093/nar/gkad733.
[20]Xu C, Li C, Chen J, et al. R-loop-dependent promoter-proximal termination ensures genome stability[J]. Nature, 2023, 621:610-619. doi:10.1038/s41586-023-06515-5.
[21]Yao Y, Gong G, Guo Z, et al. A pan-cancer analysis of ring finger protein 135 and its relationship to triple-negative breast cancer proliferation and metastasis[J]. Aging, 2022, 14:9758-9772. doi:10.18632/aging.204429.
[22]Yang H, Xue M, Su P, et al. RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast cancer[J]. J Exp Clin Cancer Res, 2022, 41:364. doi:10.1186/s13046-022-02576-y.
[23]Wegwitz F, Prokakis E, Pejkovska A, et al. The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis[J]. Cell Death Dis, 2020, 11:873. doi:10.1038/s41419-020-03081-w.
[24]Lyu Y, Yang Y, Talwar V, et al. Hypoxia-inducible factor 1 recruits FACT and RNF20/40 to mediate histone ubiquitination and transcriptional activation of target genes[J]. Cell Rep, 2024, 43:113972. doi:10.1016/j.celrep.2024.113972.
[25]Dong Q, Gong C, Jiang Q, et al. Identification of differentially expressed tumour-related genes regulated by UHRF1-driven DNA methylation[J]. Sci Rep, 2024, 14:18371. doi:10.1038/s41598-024-69110-2.

环指蛋白家族在乳腺癌中作用机制的研究进展

Advances in the mechanism of action of the ring finger proteins family in breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	金晓霞, 刘玉山, 胡继平, 朱兴华. COA6在乳腺癌中的表达及其与肿瘤免疫细胞浸润相关[J]. 基础医学与临床, 2025, 45(6): 755-761.
[2]	王盟, 沈学静, 刘佳, 尚璐璐, 张沫. 基于探针的无标记表面增强拉曼光谱(SERS)用于鉴别乳腺癌患者的血清代谢谱[J]. 基础医学与临床, 2025, 45(5): 651-657.
[3]	张柯, 陆江宁, 孙立新, 遇珑, 孙力超, 冉宇靓. TOMM40L促进三阴性乳腺癌细胞增殖和迁移并与不良预后相关[J]. 基础医学与临床, 2025, 45(5): 575-582.
[4]	楼海均, 孟·孟根, 张振宇, 童卓云, 乌都木丽. 跨膜蛋白33在肿瘤发生发展中的作用[J]. 基础医学与临床, 2025, 45(2): 258-262.
[5]	罗钰蓓, 黄建军, 杨文秀, 张军红, 李静, 赵春华, 豆晓伟. 4株患者原代细胞源的乳腺癌细胞系建立及初步研究[J]. 基础医学与临床, 2025, 45(2): 183-188.
[6]	张彦池, 施俊琦, 张一君, 段佳文, 刘进宇, 张丽燕, 梁晚平. 乳腺癌代谢机制与免疫微环境靶向的协同治疗进展[J]. 基础医学与临床, 2025, 45(12): 1662-1667.
[7]	苏凌峰, 王虎霞, 王延峰, 宋张骏. 慢性压力对乳腺癌发展的影响[J]. 基础医学与临床, 2024, 44(9): 1303-1307.
[8]	夏雨佳, 杨振丽, 代娣, 刘玉琴. 乳腺癌类器官的培养及鉴定[J]. 基础医学与临床, 2024, 44(9): 1223-1228.
[9]	陆凯, 陆建菊, 郭文利, 黄建棋, 李志华. lncRNA VIM-AS5在人乳腺癌细胞系中的表达及对乳腺癌细胞增殖和迁移的影响[J]. 基础医学与临床, 2024, 44(4): 447-453.
[10]	南璐, 郭梦杰, 高雅楠, 贾红燕. 膜联蛋白A家族成员在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(3): 393-397.
[11]	依合里曼·买买提, 曹燕珍, 王翠翠, 岳娜, 梁莉萍. PIK3CA突变与乳腺癌临床病理特征及预后的相关性[J]. 基础医学与临床, 2024, 44(3): 303-307.
[12]	李欢, 谢贤鑫. circNHSL1通过调控miR-125b-5p/HMGB3轴抑制人乳腺癌细胞系增殖及促凋亡[J]. 基础医学与临床, 2024, 44(12): 1678-1684.
[13]	李江丽, 孙静, 唐一君, 郭君兰, 陈博, 郭胜男. Circ-DDX5靶向miR-3940抑制人乳腺癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2024, 44(1): 1-7.
[14]	陈宁, 彭甜影, 张伟苗, 高亚诺, 李轩, 闫彩珍, 李军霞. 雷公藤甲素与阿霉素联用对人乳腺癌细胞系 MCF-7 的协同促凋亡作用[J]. 基础医学与临床, 2023, 43(8): 1186-1192.
[15]	王继辉, 曹吉烈, 张立军, 张军, 鹿文葆. TARBP2降解AKAP12转录本促进人乳腺癌细胞转移[J]. 基础医学与临床, 2023, 43(8): 1259-1264.